Clinical trials: Durvalumab
- Drug or intervention Durvalumab
- Funder type Industry (pharma, biotech, devices)
- Age group Children (under 18)
Pediatric Cancer, Solid Tumor Pediatric
Durvalumab and Tremelimumab for Pediatric Malignancies
The purpose of the study is to determine the recommended dose of durvalumab and tremelimumab (immunotherapy drugs) in pediatric patients with advanced solid and hematological cancers and expand in a second phase to test the…
- Conditions
- Pediatric Cancer, Solid Tumor Pediatric, Hematological Malignancies
- Trial name
- NCT03837899
- Testing
- Durvalumab / Tremelimumab Combination Therapy
- Where
- 19 sites in United States, France and 5 more
- Volunteers
- 50 people
- Sponsor
- AstraZeneca
Lung Cancer
Savolitinib Combine With Durvalumab in EGFR Wild-type Locally Advanced or Metastatic NSCLC
This is an open-label, interventional, multiple-center, exploratory Phase II study sponsored by AstraZeneca Investment(China)Co., LTD.
- Trial name
- SOUND (NCT05374603)
- Testing
- Savolitinib, Durvalumab
- Where
- 16 sites in China
- Volunteers
- 47 people
- Sponsor
- AstraZeneca
Small Cell Lung Carcinoma
A French Real-life Study: EvaluatioN of durvALumab Utilization and Effectiveness for First Line Extensive Stage Small Cell Lung Cancer.
Small cell lung cancer (SCLC), characterized by rapid proliferation, high growth fraction and early development of metastases, is the most aggressive form of lung cancer.
- Trial name
- ARSENAL (NCT05683977)
- Testing
- durvalumab
- Where
- 34 sites in France
- Volunteers
- 254 people
- Sponsor
- AstraZeneca
Small Cell Lung Carcinoma
REAL-WORLD DURVALUMAB IN EXTENSIVE-STAGE SMALL CELL LUNG CANCER
Primary lung cancer is one of the most common malignancies and causes of cancer-related death worldwide [Passiglia et al., 2019; Bade and Dela Cruz, 2020].
- Trial name
- ARAL (NCT06826677)
- Testing
- Durvalumab
- Where
- 11 sites in Italy
- Volunteers
- 71 people
- Sponsor
- AstraZeneca